search
Back to results

Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome (SOS-COVID19)

Primary Purpose

Covid19, SARS-CoV Infection

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Auricular neuromodulation
Control
Sponsored by
Fondation Ophtalmologique Adolphe de Rothschild
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Covid19 focused on measuring Non-invasive Neuromodulation, Vagus Nerve

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • COVID-19 positive inpatient (PCR or other certified test mandatory)
  • Inpatient showing at least one of the following criterion: Abnormal respiratory auscultation AND SpO2 < 94% without oxygen therapy, OR Acute Respiratory failure requiring either oxygen therapy or high-flow oxygen therapy or non-invasive respirator and/or invasive respirator.

Exclusion Criteria:

  • Inpatient requiring legal protection
  • Pregnant or breastfeeding woman
  • Intensive care inpatient or patient undergoing surgery

Secondary non inclusion criteria :

- Unintentional blinding removal.

Sites / Locations

  • Centre Hospitalier Simone Veil
  • Fondation Adolphe de Rothschild

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Auricular neuromodulation

Control

Arm Description

Outcomes

Primary Outcome Measures

Comparison of the percentage of clinically improved inpatients between D0 and D14
Inpatients are considered as clinically improved if they have gained at least 2 points on the following clinical evaluation scale, or if they went back home Clinical evaluation scale :1. Outpatient back to normal activities / 2. Outpatient without normal activities / 3. Inpatient without oxygen therapy / 4. Inpatient with oxygen therapy/ 5. Inpatient requiring either nasal high-flow oxygen therapy or non-invasive respirator or both / 6. Inpatient, requiring either ExtraCorporeal Membrane Oxygenation (ECMO) or invasive artificial respirator, or both / 7. Deceased.

Secondary Outcome Measures

Full Information

First Posted
April 7, 2020
Last Updated
April 8, 2021
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
search

1. Study Identification

Unique Protocol Identification Number
NCT04341415
Brief Title
Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome
Acronym
SOS-COVID19
Official Title
Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Terminated
Why Stopped
Inclusion stopped at 50% after interim analysis: primary efficacy endpoint not significant
Study Start Date
April 9, 2020 (Actual)
Primary Completion Date
November 20, 2020 (Actual)
Study Completion Date
January 15, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Ophtalmologique Adolphe de Rothschild

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The COVID-19 pandemic has already overwhelmed the sanitary capacity. Additional therapeutic arsenals, albeit untested in the given context but previously proven to be efficacious in a related clinical context, that could reduce the morbidity rate are urgently needed. A decrease of Heart Rate Variability (HRV) is a validated bad prognosis marker in sepsis and acute respiratory distress syndrome. In contrast, auricular vagus nerve stimulation was proven not only to increase HRV values in healthy Humans, but also to reduce sepsis and increase survival, both significantly, in experimental models. Moreover, the heavy viral infection within the brainstem of deceased patients suggests that the neuroinvasive potential of SARS-CoV2 is likely to be partially responsible for COVID-19 acute respiratory failure and may bear relevance in tailoring future treatment modalities. Interestingly, the vagus nerve (or tenth cranial nerve) connects bidirectionally the brainstem to various internal organs including the lung and to one external organ, namely, the outer ear. Hence, the impact of auricular vagus nerve stimulation through semi-permanent needles will be studied, mostly used so far for pain alleviation, on the outcome of COVID-19 inpatients within 15 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid19, SARS-CoV Infection
Keywords
Non-invasive Neuromodulation, Vagus Nerve

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Masking Description
The participants and the care providers will not know the arm of randomization. Only the principal investigator who will perform the intervention will know the type of intervention.
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Auricular neuromodulation
Arm Type
Experimental
Arm Title
Control
Arm Type
Sham Comparator
Intervention Type
Procedure
Intervention Name(s)
Auricular neuromodulation
Other Intervention Name(s)
VERUM
Intervention Description
The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room. Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient. Compress soaked with Oxygenated water on the concha (to stop potential bleeding). Placing an opaque dressing on the ear and a non-occlusive Band-Aid
Intervention Type
Procedure
Intervention Name(s)
Control
Other Intervention Name(s)
SHAM
Intervention Description
The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room. Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle). Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid.
Primary Outcome Measure Information:
Title
Comparison of the percentage of clinically improved inpatients between D0 and D14
Description
Inpatients are considered as clinically improved if they have gained at least 2 points on the following clinical evaluation scale, or if they went back home Clinical evaluation scale :1. Outpatient back to normal activities / 2. Outpatient without normal activities / 3. Inpatient without oxygen therapy / 4. Inpatient with oxygen therapy/ 5. Inpatient requiring either nasal high-flow oxygen therapy or non-invasive respirator or both / 6. Inpatient, requiring either ExtraCorporeal Membrane Oxygenation (ECMO) or invasive artificial respirator, or both / 7. Deceased.
Time Frame
14 day after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: COVID-19 positive inpatient (PCR or other certified test mandatory) Inpatient showing at least one of the following criterion: Abnormal respiratory auscultation AND SpO2 < 94% without oxygen therapy, OR Acute Respiratory failure requiring either oxygen therapy or high-flow oxygen therapy or non-invasive respirator and/or invasive respirator. Exclusion Criteria: Inpatient requiring legal protection Pregnant or breastfeeding woman Intensive care inpatient or patient undergoing surgery Secondary non inclusion criteria : - Unintentional blinding removal.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claire-Marie RANGON
Organizational Affiliation
Fondation Adolphe de Rothschild
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Simone Veil
City
Beauvais
ZIP/Postal Code
60000
Country
France
Facility Name
Fondation Adolphe de Rothschild
City
Paris
ZIP/Postal Code
75019
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
34408665
Citation
Rangon CM, Barruet R, Mazouni A, Le Cossec C, Thevenin S, Guillaume J, Leguillier T, Huysman F, Luis D. Auricular Neuromodulation for Mass Vagus Nerve Stimulation: Insights From SOS COVID-19 a Multicentric, Randomized, Controlled, Double-Blind French Pilot Study. Front Physiol. 2021 Aug 2;12:704599. doi: 10.3389/fphys.2021.704599. eCollection 2021.
Results Reference
derived

Learn more about this trial

Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome

We'll reach out to this number within 24 hrs